SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma trades jubilantly on getting USFDA's nod for Loratadine Liquid Filled Capsules

26 Sep 2016 Evaluate

Marksans Pharma is currently trading at Rs. 52.90, up by 5.05 points or 10.55% from its previous closing of Rs. 47.85 on the BSE.

The scrip opened at Rs. 47.60 and has touched a high and low of Rs. 53.85 and Rs. 47.45 respectively. So far 2903482 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 113.80 on 28-Dec-2015 and a 52 week low of Rs. 33.45 on 01-Mar-2016.

Last one week high and low of the scrip stood at Rs. 53.85 and Rs. 45.05 respectively. The current market cap of the company is Rs. 2146.85 crore.

The promoters holding in the company stood at 48.25%, while institutions and non-institutions held 13.77% and 37.98% respectively.

Marksans Pharma has received US Food & Drug Administration’s (USFDA) approval for an Abbreviated New Drug Application (ANDA) Loratadine Liquid Filled Capsules 10 mg.

Loratadine Liquid Filled Capsules 10 mg is therapeutically equivalent to the reference listed drug Claritin Liqui-Gels Capsules 10 mg of Bayer Healthcare LLC.  Loratadine is an antihistamine that reduces the effects of natural chemical histamine in the body. Loratadine is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching and other allergy symptoms.

Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.

Marksans Pharma Share Price

179.55 -0.95 (-0.53%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×